HC
PACB icon

Hurley Capital’s Pacific Biosciences PACB Stock Holding History

Hurley Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.93K Hold
2,976
– – ﹤0.01% 486
2025
Q4 		$5.57K Buy
+2,976
New +$5.72K ﹤0.01% 399

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hurley Capital's PACB Position: Q1 2026 in Review

Hurley Capital held its Pacific Biosciences (PACB) position steady in Q1 2026 at 2,976 shares worth $3.93K. The position accounts for ﹤0.01% of the portfolio, ranked #486.

Hurley Capital first reported a position in PACB in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.57K in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Hurley Capital held 2,976 shares of Pacific Biosciences worth $3.93K as of Q1 2026.
  • Hurley Capital left its Pacific Biosciences share count unchanged in Q1 2026.
  • Pacific Biosciences made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #486 holding.
  • Hurley Capital first reported a position in Pacific Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Hurley Capital's Pacific Biosciences position peaked at $5.57K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.